| abstract |
The heterocyclic amides of the formula (1) are described in which: it is a single or double bond; A is phenylene or heteroarylene; m is 0, 1 or 2; n is 0, 1 or 2; R1 is selected for example from halo, nitro, cyano, hydroxyl, carboxyl; r is 1 or 2; Y is -NR2R3 or -OR3; R2 and R3 are selected for example from hydrogen, hydroxyl, aryl, heterocyclyl and alkyl of 1 to 4 carbon atoms (optionally substituted by 1 or 2 R8 groups); R4 is selected for example from hydrogen, halo, nitro, cyano, hydroxyl, alkyl of 1 to 4 carbon atoms, and alkanoyl of 1 to 4 carbon atoms; R8 is selected for example from hydroxyl, -COCOOR9, -C (O) N (R9) (R10), -NHC (O) R9, (R9) (R10) N- and -COOR9; R9 and R10 are selected for example from hydrogen, hydroxyl, alkyl of 1 to 4 carbon atoms (optionally substituted by 1 or 2 R13); R13 is selected from hydroxyl, halo, trihalomethyl and alkoxy of 1 to 4 carbon atoms; or a pharmaceutically acceptable salt or prodrug thereof; they possess glycogen phosphorylase inhibitory activity and consequently have value in the treatment of disease states associated with increased glycogen phosphorylase activity. The processes for the manufacture of heterocyclic amide derivatives and the pharmaceutical compositions containing them. |